AC
ONCT

Armistice Capital’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Armistice Capital’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-65,808
Closed -$2.24M – 123
2020
Q3 		$2.24M Buy
65,808
+2,972
+5% +$146K 0.08% 90
2020
Q2 		$3.57M Buy
+62,836
New +$3.54M 0.16% 70

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Armistice Capital's ONCT Position: Q4 2020 in Review

Armistice Capital sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2020, closing a stake of 65,808 shares — an estimated $2.24M sold.

Armistice Capital first reported a position in ONCT in Q2 2020 and held it in 2 quarters. The position peaked at $3.57M in Q2 2020. 52 funds tracked by Wall St. Rank hold ONCT as of Q4 2020.

  • Armistice Capital reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2020 after selling out during the quarter.
  • Armistice Capital sold 65,808 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2020, an estimated $2.24M.
  • Armistice Capital first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2020 and held it in 2 quarters.
  • Armistice Capital's Oncternal Therapeutics, Inc. Common Stock position peaked at $3.57M in Q2 2020.
  • 52 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Armistice Capital's 13F filing for Q4 2020, filed 16 Feb 2021.